| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Rifampin measurement (procedure) |
Component |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Poisoning by rifampin |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Accidental rifampin poisoning (disorder) |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional rifampin poisoning |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampin poisoning of undetermined intent |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin adverse reaction (disorder) |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Allergy to rifampin |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampin overdose |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Accidental rifampin overdose |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Intentional rifampin overdose |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampin overdose of undetermined intent |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely rifampicin 150 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampicin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampicin 100mg/5mL syrup (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampin 600mg injection+solvent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampicin 300mg injection+diluent (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Isoniazid + pyrazinamide + rifampin 50mg/300mg/120mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampicin+isoniazid 150mg/100mg tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Isoniazid- and rifampicin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing isoniazid and pyrazinamide and rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Urine rifampicin level (procedure) |
Component |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Accidental rifampin poisoning (disorder) |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Intentional rifampin poisoning |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Isoniazid +rifampin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampicin-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Measurement of rifampin in serum specimen using high performance liquid chromatography (procedure) |
Component |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Allergy to rifampin |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Isoniazid- and rifampicin-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Isoniazid- and pyrazinamide- and rifampicin-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing ethambutol and isoniazid and rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing ethambutol and isoniazid and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing ethambutol and isoniazid and pyrazinamide and rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
| Product containing ethambutol and isoniazid and pyrazinamide and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
| Product containing precisely rifampicin 150 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely rifampicin 150 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 300 mg oral capsule |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin+isoniazid 150mg/100mg tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Rifampicin+isoniazid 150mg/100mg tablet (substance) |
Has basis of strength substance (attribute) |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin+isoniazid 150mg/100mg tablet (substance) |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
Has basis of strength substance (attribute) |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin sodium (substance) |
Is a |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
Has precise active ingredient |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Rifampicin 300 mg oral capsule |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely rifampicin 150 milligram/1 each conventional release oral capsule (clinical drug) |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
False |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin+isoniazid 150mg/100mg tablet (substance) |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin sodium (substance) |
Is modification of (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampicin 600 mg powder for solution for injection vial |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 600 mg powder for solution for injection vial |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely rifampicin 20 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely rifampicin 20 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Ethambutol and isoniazid and rifampicin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Ethambutol and isoniazid and pyrazinamide and rifampicin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
| Isoniazid and pyrazinamide and rifampicin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing only isoniazid and rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing only rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Ethambutol and isoniazid and pyrazinamide and rifampicin only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
| Product containing only ethambutol and isoniazid and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing only isoniazid and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing only rifampicin in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing only isoniazid and pyrazinamide and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely ethambutol hydrochloride 275 milligram and isoniazid 75 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely ethambutol hydrochloride 275 milligram and isoniazid 75 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely ethambutol hydrochloride 275 milligram and isoniazid 75 milligram and pyrazinamide 400 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
| Product containing precisely ethambutol hydrochloride 275 milligram and isoniazid 75 milligram and pyrazinamide 400 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
| Product containing precisely rifampicin 600 milligram/1 vial powder for conventional release solution for infusion (clinical drug) |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely rifampicin 600 milligram/1 vial powder for conventional release solution for infusion (clinical drug) |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 600 mg powder for solution for infusion and/or injection vial |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 600 mg powder for solution for infusion and/or injection vial |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 150 mg oral tablet |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 150 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 300 mg powder for solution for infusion vial |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 300 mg powder for solution for infusion vial |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 300 mg oral tablet |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 300 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 450 mg oral tablet |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Rifampicin 450 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Isoniazid 75 mg and rifampicin 150 mg oral tablet |
Has precise active ingredient |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Isoniazid 75 mg and rifampicin 150 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Injection of rifampicin into synovial membrane (procedure) |
Direct substance |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Measurement of rifampin in serum specimen using high performance liquid chromatography (procedure) |
Component |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Urine rifampicin level (procedure) |
Component |
True |
Rifampicin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]